Genentech kept by Bear Stearns at outperform

Genentech Inc. was maintained by Bear Stearns analyst Mark Schoenebaum at an outperform rating with a price target on the stock of $98 per share following its release of interim trial data for BCIRG-006, which could boost Herceptin's peak sales potential. Also, an FDA panel voted for approval of Tarceva for use in pancreatic cancer as well as lung cancer. Genentech shares Wednesday were down $1.17, or 1.29%, at $89.63 on volume of 4,855,900 shares versus the three-month running average of 3,400,280 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.